178 related articles for article (PubMed ID: 23839185)
21. Rituximab treatment in lupus nephritis--where do we stand?
Gunnarsson I; Jonsdottir T
Lupus; 2013 Apr; 22(4):381-9. PubMed ID: 23553781
[TBL] [Abstract][Full Text] [Related]
22. Successful use of rituximab in the treatment of childhood and juvenile pemphigus.
Vinay K; Kanwar AJ; Sawatkar GU; Dogra S; Ishii N; Hashimoto T
J Am Acad Dermatol; 2014 Oct; 71(4):669-75. PubMed ID: 25022850
[TBL] [Abstract][Full Text] [Related]
23. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
Kremer N; Snast I; Cohen ES; Hodak E; Mimouni D; Lapidoth M; Mazor S; Levi A
Am J Clin Dermatol; 2019 Apr; 20(2):209-216. PubMed ID: 30421306
[TBL] [Abstract][Full Text] [Related]
24. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients.
Hall RP; Streilein RD; Hannah DL; McNair PD; Fairley JA; Ronaghy A; Edhegard KD; Levesque MC
J Invest Dermatol; 2013 Dec; 133(12):2786-2788. PubMed ID: 23732750
[No Abstract] [Full Text] [Related]
25. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
[TBL] [Abstract][Full Text] [Related]
26. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.
Erkan D; Vega J; Ramón G; Kozora E; Lockshin MD
Arthritis Rheum; 2013 Feb; 65(2):464-71. PubMed ID: 23124321
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
28. [Bullous Pemphigoid Successfully Treated with Rituximab].
Silva N; Costa A; Salvador F; Serradeiro E
Acta Med Port; 2017 Mar; 30(3):243-246. PubMed ID: 28550834
[TBL] [Abstract][Full Text] [Related]
29. Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin.
Nguyen T; Ahmed AR
Clin Exp Dermatol; 2017 Jul; 42(5):516-519. PubMed ID: 28508388
[TBL] [Abstract][Full Text] [Related]
30. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.
Wallet-Faber N; Franck N; Batteux F; Mateus C; Gilbert D; Carlotti A; Avril MF; Dupin N
Dermatology; 2007; 215(3):252-5. PubMed ID: 17823525
[TBL] [Abstract][Full Text] [Related]
31. Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab.
Heelan K; Hassan S; Bannon G; Knowles S; Walsh S; Shear NH; Mittmann N
J Cutan Med Surg; 2015; 19(3):274-82. PubMed ID: 25775641
[TBL] [Abstract][Full Text] [Related]
32. Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience.
Suárez-Carantoña C; Jiménez-Cauhé J; González-García A; Fernández-Guarino M; Asunción Ballester M
Actas Dermosifiliogr; 2023 Jan; 114(1):T62-T68. PubMed ID: 36368587
[TBL] [Abstract][Full Text] [Related]
33. Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience.
Suárez-Carantoña C; Jiménez-Cauhé J; González-García A; Fernández-Guarino M; Asunción Ballester M
Actas Dermosifiliogr; 2023 Jan; 114(1):62-68. PubMed ID: 35868546
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
[TBL] [Abstract][Full Text] [Related]
35. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
36. [Monitoring and precautions to take during treatment with a biological immunomodulator].
Sibilia J
Rev Med Interne; 2010 Dec; 31 Suppl 3():S315-8. PubMed ID: 21036423
[No Abstract] [Full Text] [Related]
37. [Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases].
Moiseev SV; Novikov PI; Semenkova EN; Strizhakov LA; Gulyaev SV; Yanushkevich TN; Nikiforova NV; Meshkov AD; Panasyuk VV; Sokorin YD; Taranova MV; Parfenova SA; Dubrovskaya LV; Zhabina ES; Kuznetsova EI; Lopatina IA; Bulanov NM; Mukhin NA
Ter Arkh; 2013; 85(5):37-43. PubMed ID: 23819337
[TBL] [Abstract][Full Text] [Related]
38. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
39. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Maung SW; Leahy M; O'Leary HM; Khan I; Cahill MR; Gilligan O; Murphy P; McPherson S; Jackson F; Ryan M; Hennessy B; McHugh J; Goodyer M; Bacon L; O'Gorman P; Nee A; O'Dwyer M; Enright H; Saunders J; O'Keeffe D
Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468
[TBL] [Abstract][Full Text] [Related]
40. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
Novikov PI; Krivosheev OG; Semenkova EN
Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
